Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire

HAYWARD, Calif., Jan. 25, 2013

HAYWARD, Calif., Jan. 25, 2013 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH) today announced the pricing of an underwritten public offering
of 60,606,061 shares of its common stock, offered at a price of $0.66 per
share. The Company estimates that the gross proceeds from the offering,
before deducting underwriting discounts and commissions and other estimated
offering expenses payable by Anthera, will be $40.0 million. The offering is
expected to close on or about January 30, 2013, subject to customary closing
conditions. In addition, Anthera has granted the underwriters a 30-day option
to purchase up to an additional 9,090,909 shares of common stock. The Company
intends to use the net proceeds from the offering for general corporate

Jefferies & Company, Inc. is acting as sole book-running manager in the
offering and Leerink Swann LLC is acting as co-manager. Trout Capital LLC has
acted as an advisor to the Company.

The securities described above are being offered by the Company pursuant to a
shelf registration statement previously filed with, and declared effective by,
the Securities and Exchange Commission (the "SEC"). A final prospectus
supplement and accompanying prospectus relating to the offering will be filed
with the SEC and will be available on the SEC's website at Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering, when available, may be
obtained from Jefferies & Company, Inc., Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or
by telephone at 877-547-6340, or by email at

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of any such state or jurisdiction.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement
Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements include statements about the Company's expectations with respect to
its public offering, including statements about the completion and timing of
the offering, the expected gross proceeds of the offering and its intended
use of proceeds from the offering. Such statements are based on the Company's
expectations as of the date of this press release and are subject to certain
risks and uncertainties that could cause actual results to differ materially,
including but not limited to the risks and uncertainties associated with
market conditions and the satisfaction of customary closing conditions related
to the offering, as well as those set forth in the Company's public filings
with the SEC, including the Company's Annual Report on Form 10-K for the year
ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter
ended September 30, 2012. The Company disclaims any intent or obligation to
update any forward-looking statements, whether because of new information,
future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., or

SOURCE Anthera Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.